Quantcast

Latest Psoriasis Stories

2014-09-17 08:25:00

Independent, 3rd party scientists review psoriasis treatments and the benefits of small molecule drugs including CF101; PETACH TIKVA, Israel, Sept. 17, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that an article titled, "New Drugs and Treatment Targets in Psoriasis," published in the peer-reviewed scientific...

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-09-10 23:11:43

Lexington Int’l is pleased to announce the publication of the results of a clinical review with the HairMax LaserComb in a peer-review medical journal, validating efficacy for treating hereditary hair loss. Boca Raton, FL (PRWEB) September 10, 2014 Lexington Int’l is pleased to announce the publication of the results of a clinical review with the HairMax LaserComb for the treatment of hair loss, in the peer-review medical journal, the International Journal of Trichology in the April...

2014-09-08 12:24:27

TNF-Alpha Inhibitors--Including Sales Leader Humira--Accounted for Over 90 Percent of the Psoriatic Arthritis Market, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to...

2014-09-05 08:23:11

Newly Acquired SGX301 Orphan Drug Candidate Being Evaluated for Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 5, 2014 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today the acquisition of a novel orphan drug candidate, known as SGX301 (synthetic hypericin). SGX301 is poised to enter...

2014-09-02 12:30:15

Sodrec Medical Solutions, Inc. to Partner for US Sales TUSTIN, Calif., Sept. 2, 2014 /PRNewswire/ -- BioPhotas, Inc. today announced the launch of the Celluma ELITE for sale to the Aesthetic Physician Market. The LED therapy device is stand-mounted and able to be precisely positioned over an area of treatment via an articulating arm and a patented shape-taking light panel. Sodrec Medical Solutions, Inc. will be responsible for all US promotion of the Celluma ELITE and have been...

2014-09-02 08:28:57

PETACH TIKVA, Israel, Sept. 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported financial results for the six months ended June 30, 2014 and updates on its clinical programs. Clinical and Corporate Highlights Include: -- CF101 - Completes patient enrollment in Phase II/III trial for the treatment of psoriasis...

2014-08-31 23:04:24

Psoriasis is the most common autoimmune disease in the U.S. As many as 7.5 million Americans have psoriasis. Kingsport, TN (PRWEB) August 31, 2014 Premier Pharmacy hosted “Living with Psoriasis” health forum in association with August being Psoriasis Awareness Month. A large number of men and women were in attendance for the free seminar held at 109 Jack White Drive, Kingsport, TN on August 27, 2014. The public was welcome. There were various speakers that covered an assorted range of...

2014-08-26 23:14:33

The Editorial Board of Living with a Disability magazine has published an important new article on skin disorders as a disabling condition in order to mark National Psoriasis Awareness Month, which occurs every August nationwide. San Antonio. TX (PRWEB) August 26, 2014 The Editorial Board of Living with a Disability magazine has published an important new article on skin disorders as a disabling condition in order to mark National Psoriasis Awareness Month, which occurs every August...

2014-08-21 08:28:17

INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ -- -- Ixekizumab met all primary and key secondary objectives across three pivotal studies of 3,866 patients, the largest Phase 3 moderate-to-severe plaque psoriasis program to date -- Ixekizumab was superior to etanercept on all measures of skin clearance in both active comparator studies -- Lilly plans regulatory submissions for ixekizumab in 1(st) half of 2015 Eli Lilly and Company's (NYSE: LLY)...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'